argenx SE
HealthcareNASDAQ:ARGX · NASDAQ Global Select
-$0.32 today
Vol 0.19M · Avg 0.32M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $1.3B +55.6% | $833.0M +296.0% | -$425.0M +41.0% | -$720.3M -106.6% | -$348.7M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $0 -100.0% | $17.5M -84.3% | $111.3M +6.7% | $104.3M +2002.0% | $5.0M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $0 -100.0% | $235.2M +0.9% | $233.0M +48.4% | $157.0M -12.5% | $179.4M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$423.9M -30.6% | -$324.6M -5.1% | -$308.9M +17.8% | -$375.9M -10.3% | -$341.0M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$804.8M -90.5% | -$422.4M -127.5% | -$185.7M +16.5% | -$222.3M -602.6% | -$31.6M | $592.6M | $1.3B | $626.2M |
| Inventory | -$99.3M -3.6% | -$95.8M -15.4% | -$83.0M +30.4% | -$119.3M -42.2% | -$83.9M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $614.2M +149.8% | $245.9M | $0 | $0 | $0 | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$134.1M -156.3% | -$52.3M -30.2% | -$40.2M -16.4% | -$34.5M +84.7% | -$225.4M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$21.6M +97.4% | -$843.9M -2651.7% | -$30.7M -9.9% | -$27.9M +72.5% | -$101.4M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $850.5M +1127.8% | -$82.7M +80.3% | -$420.3M +51.3% | -$862.8M -42.2% | -$606.8M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$6.2M +90.9% | -$68.3M -55.9% | -$43.8M +57.8% | -$103.8M +14.5% | -$121.4M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 +100.0% | -$7.0M +46.2% | -$13.0M -550.0% | -$2.0M | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$1.5B +33.1% | -$2.2B -71.7% | -$1.3B +24.9% | -$1.7B -642.2% | -$228.2M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $2.4B +67.6% | $1.4B -7.4% | $1.5B +16.5% | $1.3B | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 -100.0% | $45.1M -9.3% | $49.8M +155.4% | -$89.8M +22.0% | -$115.2M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $823.9M +214.8% | -$717.6M -332.8% | $308.2M +166.8% | -$461.2M -32.9% | -$347.1M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 +100.0% | -$7.6M -100.9% | -$3.8M +8.7% | -$4.2M -8.0% | -$3.9M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $279.2M -9.5% | $308.7M -74.2% | $1.2B +57.3% | $761.0M -30.3% | $1.1B | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$45.5M -113.4% | -$21.3M -114.8% | $143.8M +65.3% | $87.0M +170.8% | $32.1M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $233.7M -16.5% | $279.8M -79.1% | $1.3B +58.4% | $843.8M -24.6% | $1.1B | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $83.3M +393.9% | -$28.3M -220.6% | $23.5M +143.7% | -$53.7M -8.3% | -$49.6M | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $2.0B +462.8% | -$548.9M -144.0% | $1.2B +333.8% | -$533.9M -553.0% | $117.9M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $844.3M +659.0% | -$151.0M +67.5% | -$464.1M +52.0% | -$966.6M -32.7% | -$728.2M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Regeneron Pharmaceuticals, Inc.
NASDAQ:REGN
$63.38B
Becton, Dickinson and Company
NYSE:BDX
$52.86B
Cardinal Health, Inc.
NYSE:CAH
$52.46B
Edwards Lifesciences Corporation
NYSE:EW
$48.78B
IDEXX Laboratories, Inc.
NASDAQ:IDXX
$44.09B
Haleon plc
NYSE:HLN
$40.31B
Alnylam Pharmaceuticals, Inc.
NASDAQ:ALNY
$37.92B
Agilent Technologies, Inc.
NYSE:A
$36.54B
Alcon Inc.
NYSE:ALC
$32.50B
Veeva Systems Inc.
NYSE:VEEV
$25.79B
SEC Filings
Recent regulatory filings
No filings found.
Does ARGX generate free cash flow?
argenx SE (ARGX) generated $844.30M of free cash flow in fiscal 2025.
How much operating cash flow does ARGX produce?
Operating cash flow was $850.49M, before capital expenditures of $6.18M.
Explore More
Continue the stock analysis
Jump to another research area for this company.